Cargando…
Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists
Autores principales: | Kant, Sam, Kronbichler, Andreas, Salas, Antonio, Bruchfeld, Annette, Geetha, Duvuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012272/ https://www.ncbi.nlm.nih.gov/pubmed/33821223 http://dx.doi.org/10.1016/j.ekir.2021.03.876 |
Ejemplares similares
-
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
por: Kant, Sam, et al.
Publicado: (2021) -
Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
por: Kant, Sam, et al.
Publicado: (2022) -
Challenges of defining renal response in ANCA-associated vasculitis: call to action?
por: Odler, Balazs, et al.
Publicado: (2023) -
Additional Refinement of CKD Prognostication Using Lymphatic Vessel Density: IgA Nephropathy as the Role Model?
por: Kronbichler, Andreas, et al.
Publicado: (2022) -
Renal Involvement of CD20-Negative Intravascular Large B Cell Lymphoma with Neurological Manifestations
por: Aqeel, Faten, et al.
Publicado: (2022)